{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:16:14Z","timestamp":1789434974950,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013262","name":"First Affiliated Hospital of Guangzhou Medical University National Key Laboratory of Respiratory Diseases Clinical Experiment Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2301101"],"award-info":[{"award-number":["2021YFC2301101"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijid.2025.107965","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T11:07:08Z","timestamp":1750849628000},"page":"107965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical trial landscape for pneumonia: Evolving agents against bacterial pathogens"],"prefix":"10.1016","volume":"158","author":[{"given":"Du","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengda","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ijid.2025.107965_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.crmeth.2024.100798","article-title":"Design optimization of geometrically confined cardiac organoids enabled by machine learning techniques","volume":"4","author":"Kowalczewski","year":"2024","journal-title":"Cell Reports Methods"},{"issue":"1","key":"10.1016\/j.ijid.2025.107965_bib0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41479-022-00096-z","article-title":"Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns","volume":"14","author":"Assefa","year":"2022","journal-title":"Pneumonia (Nathan Qld.)"},{"issue":"1","key":"10.1016\/j.ijid.2025.107965_bib0003","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12916-025-04009-x","article-title":"tesG expression as a potential clinical biomarker for chronic Pseudomonas aeruginosa pulmonary biofilm infections","volume":"23","author":"Wannigama","year":"2025","journal-title":"BMC Medicine"},{"issue":"9","key":"10.1016\/j.ijid.2025.107965_bib0004","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1021\/acs.jmedchem.1c00375","article-title":"Discovery and optimization of DNA gyrase and topoisomerase IV inhibitors with potent activity against fluoroquinolone-resistant gram-positive bacteria","volume":"64","author":"Lapointe","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.ijid.2025.107965_bib0005","doi-asserted-by":"crossref","first-page":"8202","DOI":"10.1038\/s41467-024-52557-2","article-title":"BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections","volume":"15","author":"Hameed","year":"2024","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/j.ijid.2025.107965_bib0006","article-title":"Seconeolitsine, the novel inhibitor of DNA topoisomerase I, protects against invasive pneumococcal disease caused by fluoroquinolone-resistant strains","volume":"10","author":"Tirado-V\u00e9lez","year":"2021","journal-title":"Antibiotics (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.ijid.2025.107965_bib0007","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S2214-109X(18)30408-X","article-title":"Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis","volume":"7","author":"McAllister","year":"2019","journal-title":"The Lancet. Global health"},{"issue":"5","key":"10.1016\/j.ijid.2025.107965_bib0008","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1016\/S2666-5247(23)00031-9","article-title":"Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020: a national surveillance study","volume":"4","author":"Liu","year":"2023","journal-title":"The Lancet. Microbe"},{"issue":"11","key":"10.1016\/j.ijid.2025.107965_bib0009","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","article-title":"Risk factors for community-acquired pneumonia in adults in Europe: a literature review","volume":"68","author":"Torres","year":"2013","journal-title":"Thorax"},{"issue":"9875","key":"10.1016\/j.ijid.2025.107965_bib0010","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(13)60222-6","article-title":"Global burden of childhood pneumonia and diarrhoea","volume":"381","author":"Walker","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.ijid.2025.107965_bib0011","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.mcna.2018.12.008","article-title":"Community-acquired pneumonia and hospital-acquired pneumonia","volume":"103","author":"Lanks","year":"2019","journal-title":"The Medical clinics of North America"},{"issue":"10459","key":"10.1016\/j.ijid.2025.107965_bib0012","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"10325","key":"10.1016\/j.ijid.2025.107965_bib0013","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.ijid.2025.107965_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.100992","article-title":"Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses","volume":"6","author":"Melchiorri","year":"2025","journal-title":"The Lancet. Microbe"},{"issue":"206-07","key":"10.1016\/j.ijid.2025.107965_bib0015","article-title":"Novel synthetic anitmicrobial peptides against streptococcus pneumoniae","volume":"45","author":"Jindal","year":"2016","journal-title":"International Journal of Infectious Diseases"},{"issue":"107431","key":"10.1016\/j.ijid.2025.107965_bib0016","article-title":"Recent developments of topoisomerase inhibitors: clinical trials, emerging indications, novel molecules and global sales","volume":"209","author":"Bondarev","year":"2024","journal-title":"Pharmacol Res"},{"issue":"10","key":"10.1016\/j.ijid.2025.107965_bib0017","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1021\/acsinfecdis.4c00218","article-title":"A review of antibacterial candidates with new modes of action","volume":"10","author":"Butler","year":"2024","journal-title":"ACS Infect Dis"},{"issue":"9","key":"10.1016\/j.ijid.2025.107965_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00490-18","article-title":"Pharmacokinetics, tolerability, and safety of Murepavadin, a novel antipseudomonal antibiotic, in subjects with mild, moderate, or severe renal function impairment","volume":"62","author":"Dale","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ijid.2025.107965_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00977-19","article-title":"Potent LpxC inhibitors with In vitro activity against multidrug-resistant Pseudomonas aeruginosa","volume":"63","author":"Krause","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.ijid.2025.107965_bib0020","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","article-title":"Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study","volume":"9","author":"Pirnay","year":"2024","journal-title":"Nat Microbiol"},{"issue":"1","key":"10.1016\/j.ijid.2025.107965_bib0021","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40560-024-00759-7","article-title":"Current status of bacteriophage therapy for severe bacterial infections","volume":"12","author":"Sawa","year":"2024","journal-title":"Journal of Intensive Care"},{"key":"10.1016\/j.ijid.2025.107965_bib0022","unstructured":"Technophage, SA. Phase 1\/2a to assess the safety and tolerability of TP-122A for the treatment of ventilator-associated pneumonia (RECOVER)[EB\/OL]. 2024 [accessed June 01, 2025]. https:\/\/clinicaltrials.gov\/study\/NCT06370598;%20https:=#contacts-and-locations."},{"key":"10.1016\/j.ijid.2025.107965_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2020.122319","article-title":"Synthesis of biosurfactant stabilized silver nanoparticles, characterization and their potential application for bactericidal purposes","volume":"393","author":"Bezza","year":"2020","journal-title":"J Hazard Mater"},{"issue":"13","key":"10.1016\/j.ijid.2025.107965_bib0024","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab Vedotin: First Global Approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ijid.2025.107965_bib0025","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1038\/s41467-024-47741-3","article-title":"Targeted small molecule inhibitors blocking the cytolytic effects of pneumolysin and homologous toxins","volume":"15","author":"Aziz","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2025.107965_sbref0026","series-title":"Cellics Therapeutics Receives First IND Allowance by FDA for Its Innovative Cellular Nanoparticle (CNP) Technology[EB\/OL]","year":"2022"},{"key":"10.1016\/j.ijid.2025.107965_sbref0027","series-title":"A Multicenter, Randomized, Double-blind, Placebocontrolled Phase Ib\/IIa trial of CTI-005 in Methicillin-resistant\/-Sensitive Staphylococcus Aureus (MRSA\/MSSA) Pneumonia Patients[EB\/OL]","year":"2025"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225001894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225001894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:13:38Z","timestamp":1762366418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225001894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":27,"alternative-id":["S1201971225001894"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.107965","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trial landscape for pneumonia: Evolving agents against bacterial pathogens","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.107965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"107965"}}